Some authors showed that whole-body PSMA-TV and TL-PSMA values are being used for treatment response evaluation in patients with metastatic PCa and are among the most valuable parameters for evaluation of therapy response and prediction of survival rates (26, 27). The gene discussed is FOLH1; the disease is posterior cortical atrophy.